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INTRODUCTION.
CHAPTER – 1
INTRODUCTION
1.1 History of Use of Traditional Herbal Medicines
“ Traditional medicine is the sum total of the knowledge, skills and practices
based on the theories, beliefs, and experiences indigenous to different cultures,
whether applicable or not, used in the maintenance of health as well as the
prevention, diagnosis, improvement ore treatment of physical and mental illness”
(Anupama Singh, et al)
In many countries, a large proportion of the population relies on traditional
practitioners and their armamentarium of medicinal plants in order to meet health
care needs. Herbal medicines have maintained their popularity for historical and
cultural reasons. Such products have become more widely available commercially,
especially in developed countries. (International Agency for Research on Cancer,
Volume 82)
1.2 Herbal Medicinal System in India
Herbal medicines are “plant derived materials or products with therapeutic or
other human health benefits which contain either raw or processed ingredients from
one or more plants”. The traditional Indian system of medicine has a very long term
history of usage in a number of diseases and disorders, but lacks recorded safety and
efficacy data. Development of standardized, safe and effective herbal formulations
with proven scientific evidence can provide an economical alternative in several
disease areas. This reveals the possibility to recast and develop the Indian traditional
System of medicines in this manner with disease specific perspective. (Kamlesh K
Bhutani, et al). Arunachal Pradesh in North East India is reported to have more than
545 species of orchids which is the highest number of orchid species known from
any single state of India. This gives an initial advantage for observing and
scrutinizing the rich flora and fauna for development of traditional knowledge.
(Chandra Prakash Kala, et al)
Apart from the initiative to preserve the flora and fauna, various efforts have
been undertaken by the Government of India in the form of a coordinated
programme involving 19 CSIR laboratories, few academic departments and
Research and Development (R&D) institutes in the field of traditional medicines.
Their main aim is to discover new bioactive molecules from natural sources. Golden
Triangle Partnership (GTP) has also been introduced for the validation of traditional
Ayurvedic drugs. Its main objective is to bring safe, effective and standard
Ayurvedic formulations along with Siddha, Unani and Homeopathy. (K.K. Bhutani ,
et al)
There are about 45,000 plant species in India mainly in the regions of
Eastern Himalayas, Western Ghats and Andaman and Nicobar Island. The officially
documented plants with medicinal potential are 3000 but traditional practitioners use
more than 6000. India is the largest producer of medicinal herbs and is appropriately
called the botanical garden of the world. There are about 250,000 registered medical
practitioners of the Ayurvedic system and in rural India 70 % of the population is
dependent on the traditional system of medicine, the Ayurveda.
The major hindrance in the amalgamation of herbal medicines into modern
medical practices is the lack of scientific and clinical data, and better understanding
of efficacy and safety of the herbal products. To overcome these challenges and to
ensure the quality and safety of its products and practices, standardization is of vital
importance. (S.D. Seth, et al)
1.3 An overview on Current Status of Herbal Drugs in India
Herbal medicines are currently in demand and their popularity is increasing
day by day. India is a vast repository of medicinal plants that are used in traditional
medical treatments. The various indigenous systems such as Siddha, Ayurveda,
Unani and Allopathy use several plant species to treat different ailments. The use of
herbal medicine is becoming popular due to toxicity and side effects of Allopathic
medicines. This led to the sudden increase in the number of herbal drug
manufacturers. Herbal drug practices continue today because of its biomedical
benefits as well as place in cultural beliefs in many parts of the world and have made
a great contribution towards maintaining human health. Currently majority of the
world’s population depends on plant derived medicine for the first line of primary
health care for human alleviation because it has no side effects. (Sheetal Verma, et
al)
Herbal drugs constitute a major share of all the officially recognized systems
of health in India viz. Ayurveda, Yoga, Unani, Siddha, Homeopathy and
Naturopathy except Allopathy. More than 70% of India’s population still use these
non allopathic supplements, as per the Indian Drugs Act. However, there is vast
experiential evidence based for many of the natural drugs. This offers immense
opportunities for Observational Therapeutics and Reverse Pharmacology. Evidence
based herbals are widely used in the diverse systems and manufactured, as per the
pharmacopoeial guidelines, by a well organized industry. Significant basic and
clinical research has been carried out on the medicinal plants and their formulations
with the state-of-the-art methods in a number of Institutes/Universities. Indian
medicinal plants also provide a rich source for antioxidants that are known to
prevent/delay different diseased states. The medicinal plants also contain other
beneficial compounds like ingredients for functional foods, spices, also used for
home remedies. (A.D.B. Vaidya, et al)
1.4 Standardization of Traditional Medicine
Standardized herbal preparations are those which consist of complex
mixtures of one or more plants which contain plant parts of plant material in the
crude or processed state as active ingredients.
Plant constituents may be toxic but the adverse effect of such
phytotherapeutic agents are less frequent compare to synthetic drugs. Plants contain
several constituents some of which are present at very low concentrations. Very
rarely phytochemical investigations succeed in isolating and characterizing all
secondary metabolites present in the metabolites. Quality control and
standardization of herbal medicines involved several steps out of which the source
and quality of raw materials play a pivotal role in assuring the quality and stability
of herbal preparations. Other factors such as use of fresh plants, temperature, light
exposure, water availability, nutrients, period and time of collection, method of
collection, drying, packing, storage and transportation of raw materials, age and part
of the plant collected etc can greatly affect the quality and therapeutic value of
herbal medicines. Some plant constituents are heat labile so they need to be dried at
low temperatures. Also, other active constituents are destroyed by enzymatic
processes that continue for long time after plant collection. Thus proper
standardization and quality control of raw materials and herbal preparations should
be carried out. Marker substances are established for analytical purposes in case if
the active principles of the plants materials are unknown. Also other factors such as
method of extraction and contamination of microorganisms, heavy metals, pesticides
etc can also interfere with the quality, safety and efficacy of herbal drugs. Thus,
pharmaceutical companies prefer using cultivated plants instead of wild plants.
Other process of standardization such as thin layer chromatography, gas
chromatography, high performance liquid chromatography, mass spectrometry, infra
red spectrometry, ultra violet visible spectrometry can used alone or in combination
for standardization. (J.B. Calixto, et al)
1.5 Legal Status of Medicinal Plants in India
1.5.1 Background information
For centuries, Ayurveda, Siddha, and Unani systems of medicine have
coexisted with yoga, naturopathy, and homeopathy.
Ayurveda means ‘science of life’. Ayurvedic philosophy is attached to sacred
texts, the Vedas, and based on the theory of Panchabhutas - all objects and living
bodies are composed of five basic elements: earth, water, fire, air and sky. Siddha
means ‘perfection’. Siddha has close similarities to Ayurveda, the difference
between these two systems being more linguistic. Unani is based on theory of the
four bodily humours: blood, phlegm, yellow bile, and black bile. It is also called
Arabic medicine. Yoga was propounded by Patanjali and is based upon observance
of austerity, physical postures, breathing exercises, restraining of sense organs,
contemplation, meditation and Samadhi.  Naturopathy is a system of drugless
treatment and a way of life. Homeopathy has few basic principles-law of similarity,
direction of cure, principle of single remedy, the theory of minimum diluted dose,
and the theory of chronic disease.
1.5.2 Regulatory situation
Ayurveda, Unani, Siddha, Naturopathy, Homeopathy and Yoga are all
recognized by the Government of India. The first step in granting this recognition
was the creation of the Central Council of Indian Medicine Act of 1970. The main
mandates of the Central Council are as follows-
 To standardize training by prescribing minimum standards of education in
traditional medicine, although not all traditional medicine practitioners and
homeopaths need be institutionally trained to practice;
 To advise the Central Government in matters relating to
recognition/withdrawal of medical qualifications in traditional medicine in
India:
 To maintain the central register of Indian medicine, revise the register from
time to time, prescribe standards of professional conduct and etiquette, and
develop a code of ethics to be observed by practitioners of traditional
medicines in India. All traditional medicine practitioners and homeopaths
must be registered to practice.
The Central Council of Homeopathy, constituted in 1973, has the same
mandates. The Indian Government created the Department of Indian system of
Medicines and Homeopathy in March 1995.The primary areas of work for the
Department is education, standardization of medicines, enhancement of availability
of raw materials, research and development, information dissemination,
communication, and the involvement of traditional medicine and Homeopathy in
National health care. More than 4000 personnel work in these areas.
The Indian Government seeks the active and positive use of traditional
medicine and homeopathy in national health programmes, family welfare
programmes, and primary health care.
1.5.3 Education and training
Through the Central Council of Indian Medicine and the Central Council of
Homeopathy, the Indian Government is working to standardize the training of
traditional medicine practitioners and Homeopaths. In support of this, seven national
institutes are under the control of the Department of Indian Systems of Medicine and
Homeopathy:
 National Institute of Ayurveda: established in 1976, located in Jaïpur, offers
a PhD and MD in Ayurveda;
 National Institute of Homeopathy: established in 1975, located in Calcutta,
offers Bachelors and MD degrees in Homeopathy;
 National Institute of Naturopathy: established in 1984, located in Pune,
offers talks in Hindi and Marathi and programmes for teachers and doctors;
 National Institute of Unani Medicine: established in 1984, located in
Bangalore, offers postgraduate research opportunities in Unani;
 National Institute of Postgraduate Teaching and Research in Ayurveda:
located in New Delhi, offers PhD and MD degrees in Ayurveda;
 National Academy of Ayurveda: established in 1988, located in New Delhi,
offers a Degree of Membership Certificate in Ayurveda;
 National Institute of Yoga: established in 1976, located in New Delhi, offers
a one year diploma in Yoga. (Dr. Xiaorui Zhang,  et al)
1.6 Legal Rights of Medicinal Plants in India
1.6.1 Intellectual Property Rights (IPR) for Herbal Medicine
The Intellectual Property Rights (IPR) for medicinal plants and herbal
medicine emerges in two different backgrounds
1. Those that are found in nature as wild Medicinal Plants and collected for
use, and
2. Those that are developed through plant breeding systems and used as
cultivated Medicinal Plants. Plant breeding systems used so far are
mostly conventional based on selection and control pollination.
Intellectual Property Rights was established in 1990 for uniting the
indigenous people, scientific organisation and environmental groups to create and
implement forceful strategies for the use of traditional knowledge and involvement
of local people in conservation of medicinal plants. Traditional resource rights
(TRP) also have many “Bundles of Rights” related to protection, conservation and
compensation for the benefit of indigenous people.
1.6.2 Herbal Medicinal Plants and Intellectual property laws
It was thought that Agreement on Agriculture is the central focus of World
Trade Organisation (WTO) negotiations, since agricultural is a lifeline of
development of most countries in the world. It plays a pivotal role in ensuring food
security, providing livelihoods, generating foreign exchange and determining the
allocation of natural resources. Dominant interest within the Agreement on
Agriculture circles around greater market access and increases volume of
commodity flows. Agreement on Trade Related Intellectual Property Rights
(TRIPS) is the outcome of WTO which is direct impact on farmer’s livelihood, food
security and economic development of the country. TRIPS provide common
protection and enforcement of IPR such as copy rights, trademarks and patents and
also make rules intended to limit international trade in counterfeit goods. (Paramita
Nandy, et al)
1.7 Safety and efficacy of Herbal Medicine
1.7.1 Safety of Herbal Medicine
Many cases are reported on serious adverse effects after administration of
herbal products. Toxicity has also been traced due to contamination and adulteration.
Some herbal medicine can also be highly toxic. As a whole, herbal medicine can
have various adverse effect and drug-food interactions. Therefore assessment of
safety of herbal products is the first priority in herbal research.
The toxic effects of herbal preparation may be due to
A) Inherent toxicity of plant constituents and ingredients
B) Manufacturing malpractices and contamination
C) Evaluation of toxic effects of herbal formulation requires detailed
phytochemical and pharmacological studies. However the use of toxic plants
has been largely eliminated and recent reports of toxicity could be due to
misidentification and overdosing of certain constituents. Potential
contaminants include microorganisms, microbial toxins, pesticides,
fumigation agents, radioactivity, and the presence of toxic compounds of
toxic metals.
1.7.2 Assessment of toxicity
It can be done by the following technique
A) in vivo techniques
B) in vitro techniques
C) cell line techniques
D) micro array and other modern technique
E) standardization
F) techniques to adequately model toxicity.
1.7.3 Efficacy of Herbal Medicine
The efficacy of herbal medicine is the measure of its ability to improve
health and well being. Traditional medicine usually takes a “holistic” approach
where the physical, mental and social well being of an individual is treated. Thus
medicinal value of herbal products is related to its nutritional and psychological
aspects. The concept of World Health Organisation (WHO) is to emphasise the best
art of physical and mental system through which it may be able to design
appropriate indicators of efficacy and practical methodology to test them.
1.7.4 Assessment of efficacy
Presently, there is no way to assess efficacy of herbal medicines other than
by conventional clinical trial methodologies, in which efficacy is assessed by
clinical, laboratory, or diagnostic outcomes:
A) Clinical outcomes include parameters such as improved morbidity and
mortality, reduced pain or discomfort, improved appetite and weight gain,
reduction of blood pressure, reduction of tumour size and extent, and
improved quality of life.
B) Laboratory/other diagnostic outcomes include parameters such as reduction
of blood glucose, improvement of haemoglobin status, reduction of obesity
as measured by radiological or imaging techniques, and improvement in
electrocardiogram (ECG) findings. (M. Mosihuzzaman, et al)
1.8 Future status of Herbal Medicine
The uses of plants in medicine will continue in future, as a source of
therapeutic agents, and as raw material based for the extraction of semi-synthetic
chemical compounds such as cosmetics, perfumes and food industries. Recently
even developed countries are using medicinal systems that involve the use of herbal
drugs and remedies. Undoubtedly the demand for plant-derived products has
increased worldwide. The demand is estimated to grow in the years to come fuelled
by the growth of sales of herbal supplements and remedies. This means that
scientists, doctors and pharmaceutical companies will be looking at countries like
India, China etc. for their requirements, as they have the most number of medicinal
plant species and are the top exporters of medicinal plants. (Sheetal Verma, et al)
1.9 Drug discovery from Plants
Drug discovery process from natural products has been undertaken by the
Council of Scientific and Industrial Research along with various institutes and
Golden Triangle Partnership. Apart from these, there are unfortunately, very few
industries, when it comes to drug discovery from plants. Most of them restrict their
focus on herbal formulations. The enormous cost involved in isolation of pure
compounds from plants is perhaps the prohibitive factor. Therefore, most of the
natural products research for drug discovery perspective remains as an academic
exercise rather than a full fledged program.
Traditional Indian Medicine
Pro’s Con’s Areas needing improvement
Long term history of usage Batch to batch variation Quality control
Efficacy Authentification of raw Regulatory controls
material
Wider public acceptance        Lack of clinical trials data Standardization of formulations
Lower costs Lack of reference standards Good agricultural practices
Inherent photochemical Good manufacturing practices
variations
Lack of proper Development of monographs
pharmacopoeias
Table No. 1.1 Traditional Indian Medicine
Table No. 1.2 Process of Drug Delivery from Plants
Phytochemical Traditional Medicinal
Products investigation
Selection  of plants
Plant collection,
identification and authentification
Crude extracts/Pure Compound Libraries
Target based bioassays-In vitro/In vivo assays
Drug discovery
Synthetic modification required
No Yes
Bioactive compound Medicinal chemistry
and combinatorial chemistry
approaches
Toxicology and pharmacokinetic parameters
Drug development                 Drug delivery methods
Drug candidate
Clinical trials
(K. K. Bhutani, et al)
1.10 Cancer
Introduction
Cancer is a term used for diseases in which abnormal cells divide without
control and are able to invade other tissues. Cancers cells can spread to other parts of
the body through blood and lymph systems. (Harold Varmus, et al)
Cancer is a generic term used to encompass a group of diseases sharing
common characteristics. It is mainly characterized by their unregulated growth and
spread of cells to other part of the body. Its treatment is not only dependent upon
which type of malignancy (cancer) they have, but also on the extent of its spread,
together with its sensitivity to treatment. Assessment of cancer is done by meeting
the physical, psychological and social needs of the patient. Any cell can undergo
malignant changes and developed a carcinoma. Cancerous cell are not confined to
localised overgrowth and infiltration of surrounding tissue, but can spread to other
parts of the body via the lymphatic system and blood tissue, creating secondary
deposits known as “metastases”. This occurs when normal cell control mechanism
fails or disrupts. Microscopic examination of the surgical resection margins reveals
the presence of malignant cells. Left untreated, these cells will result in localised
recurrence of cancer and spread (metastasis). The earlier a cancer is detected, the
less likely it is to metastasize, and so the more favourable will be the prognosis for
the individual. (Janice Gabriel, et al)
Origins of Cancer
All cancers begin in cells, the body’s basic unit of life. To understand
cancer, it’s helpful to know what happens when normal cells become cancer cells.
The body is made up of many types of cells. These cells grow and divide in a
controlled way to produce more cells as they are needed to keep the body healthy.
When cells become old or damaged, they die and are replaced with new cells.
However, sometimes this orderly process goes wrong. The genetic material
deoxyribonucleic acid (DNA) of a cell can become damaged or changed, producing
mutations that affect normal cell growth and division. When this happens, cells do
not die when they should and new cells form when the body does not need them.
The extra cells may form tissue called a tumor.
Fig. 1.1 Cancerous cell with loss of normal growth
Causes of Cancer
It was already known that cancer could be caused by chemicals, radiations,
viruses and sometimes genetic. But with the growing knowledge of DNA and genes,
it is known that damage to DNA by chemicals and radiation, or the introduction of
new DNA sequences by virus is the most common cause of development of cancer.
Cancer causing agents are called carcinogens. These carcinogens causes
genetic damage (mutations), these mutations lead to abnormal group of cells called
clones. These mutant clones evolved to more malignant clones. Thus cancer
progress by more genetic damage and mutations. Normal cells with damaged DNA
die, cancer cells with damage DNA do not. (American cancer society report)
Cancer Control
Cancer control aims to reduce the incidence and mortality of cancer, and to
enhance the quality of those affected by cancer, through an integrated and
coordinated approach directed to primary prevention, early detection, treatment,
rehabilitation and palliation.
If cancer control outcomes are to be improved, the population to be served
must be the whole population comprising of: the healthy, the high risk, and those
who harbour asymptomatic (pre-clinical) cancer; those with a cancer diagnosis who
need treatment; those who are living with cancer as a chronic disease; those who are
‘cured’ of their cancer; and those who are dying of their cancer and require measures
to bring dignity and comfort to the end of life. Cancer control is as much about
health, its promotion and maintenance, as it is about managing the disease, cancer.
(Mark Elwood, et.al)
Symptoms
Since cancer can arise from a wide variety of sites and developed with many
differing patterns of spread, there are no clear cut symptoms for cancer. Cancer is
unlike many more specific disease or arthritic disease. The precise nature symptoms
of cancer depends not only on primary site but specifically where the tumor is
located in an organ, rate of development and also secondary spread is present or not.
Many primary tumors cause swelling or lump if they arise at a visible or accessible
part of the body, such as a skin, breast, testicle or oral cavity. A typical swelling due
to a cancer is initially painless, through ulceration (skin breakdown) can occur,
which may then become painful.
Staging of malignant disease
In order to ensure that a patient can be advised as to the most appropriate
management of their particular disease, it is vital that the extent of their cancer is
known. For example, if a patient presented with a breast lump, which proved to be
malignant, it would be inappropriate to offer the patient a mastectomy if the cancer
had already spread to the liver. Removal of the breast would not affect the patient’s
prognosis, because the cancer had already metastasized at the time of diagnosis. This
is why it is so important to ‘stage’ a patient’s cancer before detailed discussions can
take place regarding the most appropriate treatment option.
Diagnosis of cancer
The following tests can confirm or eliminate a primary (diagnose), or
determined the spread or the malignancy (stage). This investigation fall into three
main groups-
1. Radiology
2. Pathology
3. Endoscopy
Radiology
It allows visualization of the internal structures as images. These images can
be created in a number of ways such as X-rays, Computerised axial tomography
(CAT or CT scan), Magnetic resonance imaging (MRI), Ultrasound, Nuclear
medicine imaging, Positron emission tomography (PET).
Pathology
Pathology tests can confirm a clinical diagnosis and it can monitor a patient’s
disease and response to treatment. The various tests include biochemistry,
monoclonal antibodies, tumor markers, biopsy, and cytology.
Endoscopy
It involves the passage of a long flexible bundle of fibre optic lights. It
allows the operative to get a clear picture of the organs being examined thereby
obtaining tissues sample for histological examinations. (Janice Gabriel, et al)
Treatment of Cancer
There are four standard methods of treatment of cancer: surgery,
chemotherapy, radiation therapy and immunotherapy/biologic therapy. When
initially diagnosed with cancer, a cancer specialist (called an oncologist) will
provide the patient with cancer treatment options. The specialist will recommend the
best treatment plan based on the type of cancer, how far it has spread, and other
important factors like age and general health.
Ultimately, it is the patient who makes the treatment decisions based on
doctor’s recommendation, possible second opinions, and other information gathered
from qualified professionals.
Cancer Prevention
Most people do not realise that cancer is preventable in many cases. The first
step in cancer prevention is to learn what causes cancer and what its risk factors are.
Many risk factors can be avoided, thus reducing the chances of cancer but cancer
risks like genetics cannot be avoided. (Lisa Fayed, et al)
Benign and Malignant Tumors
Not all tumors are cancerous; tumors can be benign or malignant.
 Benign tumors aren't cancerous. They can often be removed, and, in most
cases, they do not come back. Cells in benign tumors do not spread to other parts of
the body.
 Malignant tumors are cancerous. Cells in these tumors can invade nearby
tissues and spread to other parts of the body. The spread of cancer from one part of
the body to another is called metastasis.
Fig. 1.2 Malignant versus Benign tumors
Types
Cancer types can be grouped into broader categories. The main categories of
cancer include:
 Carcinoma - cancer that begins in the skin or in tissues that line or
cover internal organs.
 Sarcoma - cancer that begins in bone, cartilage, fat, muscle, blood
vessels, or other connective or supportive tissue.
 Leukaemia - cancer that starts in blood-forming tissue such as the
bone marrow and causes large numbers of abnormal blood cells to be
produced and enter the blood.
 Lymphoma and myeloma - cancers that begin in the cells of
the immune system. (Harold Varmus, et al)
1.10.1 Cervical Cancer
Fig. 1.3 Cervical Cancer
Definition
Cervical cancer is a cancer that starts in the cervix, the lower part of the
uterus (womb) that opens at the top of the vagina. Cervical cancer is the third most
common type of cancer in women.
Cervical cancers start in the cells on the surface of the cervix. There are two
types of cells on the cervix’s surface: squamous and columnar. The majority of
cervical cancers are from squamous cells.
Development of cervical cancer
The development of cervical cancer is usually very slow. It starts as a pre-
cancerous condition called dysplasia. This pre-cancerous condition can be detected
by a Pap smear and is 100% treatable. That is why it is so important for women to
get regular Pap smears. Most women that are diagnosed with cervical cancer today
either have not had regular Pap smears or they have not followed up on abnormal
results.
Undetected pre-cancerous changes can develop into cervical cancer and
spread to the bladder, intestines, lungs, and liver. It can take years for pre-cancerous
changes to turn into cervical cancer. Patients with cervical cancer do not usually
have problems until the cancer is advanced and has spread.
Causes of cervical cancer
Almost all cervical cancers are caused by HPV (human papilloma virus).
HPV is a common virus that is spread through sexual intercourse. There are many
different types of HPV, and many do not cause problems. However, only certain
strains of HPV actually lead to cervical cancer. Other strains may cause genital
warts.
Risk factors of cervical cancer
Risk factors of cervical cancer include-
 Having sex at an early stage.
 Multiple sexual partners.
 Sexual partners who have multiple partners or who participate in high-risk
sexual activities.
 Women whose mothers took the drug DES (diethylstilbestrol) during
pregnancy in the early 1960’s to prevent miscarriage.
 Weakened immune system.
 Poor economic status (may not be able to afford regular Pap smears).
Fig. 1.4 Cervix view through speculum
1.10.2 Colon Cancer
Definition
Cancer that forms in the tissues of the colon (the longest part of the large
intestine) is called colon cancer. Most colon cancers are adenocarcinomas (cancers
that begin in cells that make and release mucus and other fluids).
Fig. 1.5 Normal Colon and Rectum
Fig. 1.6 Colon tumour
Prevention
Colon cancer is often one of the most preventable cancers since it frequently
develops from polyps that can be detected and removed before they become
cancerous. To help prevent cancer of the colon-
 Get regular screening tests.
 Exercise regularly, and maintain a healthy weight.
 Eat a diet rich in fruits, vegetables and whole grains
 Do not smoke and do not drink alcohol excessively
Risk factors for colon cancer
A risk factor is something that may increase the chance of developing a disease.
 Men and women aged 50 and older: More than 90% of people with this
cancer are diagnosed after the age of 50.
 People with a personal or family history of colon cancer benign (not
cancerous) colorectal polyps.
 People with a personal family history of inflammatory bowel disease,
ulcerative colitis or Crohn’s disease.
 People who use tobacco.
Symptoms of colon cancer
The presence of a symptom does not mean that one has colon cancer but one
should consult a physician if any of the following symptoms are noticed:
 Changes in bowel habits such as having diarrhoea or constipation.
 Stools that are narrower than usual (may be described as pencil-shaped).
 Frequent or general stomach discomfort (bloating, fullness or cramps).
 Diarrhoea, constipation or feeling that he bowel does not empty completely.
 Frequent gas pains.
 Weight loss for no apparent reason.
 Constant tiredness.
 Having nausea and/or vomiting. (Abdallah Elsayd Mohamdeen, et al)
1.11 Plant Source as Anticancer Agent
The use of natural substances to inhibit carcinogenesis is a rapidly evolving
aspect of cancer research. Cancer is a major public health burden in both developed
and developing countries. Plant derived agents are being used for the treatment of
cancer. In recent years, medicinal plants have attracted a lot of attention globally.
Since long time evidence has accumulated to demonstrate promising potential of
medicinal plants used in various traditional, complementary and alternative systems
especially for cancer treatment. Several medicinal plants have been studied for anti
cancer pharmacological activity in recent years. To understand the mechanism of
action, the researchers have worked at molecular level and several significant
phytochemicals have been isolated based on the activity analysis of the medicinal
plant extracts with different solvents.
Medicinal herbs are also significant source of synthetic and herbal drugs. So
far, pharmaceutical companies have screened more than 25,000 plants for anti-
cancer drugs. This should tell us that looking for single ingredients to attack cancer
might be missing the point. Just as cancers are a product of disturbances in the body,
so herbs can correct the disturbances as well as control many cancers. Herbal system
of medicine has been practiced for thousands of years. Herbal medicines have a vital
role in the prevention and treatment of cancer and medicinal herbs are commonly
available and comparatively economical. A great deal of pharmaceutical research
done in technologically advanced countries like USA, Germany, France, Japan and
China has considerably improved quality of the herbal medicines used in the
treatment of cancer. Some herbs protect the body from cancer by enhancing
detoxification functions of the body. Certain biological response modifiers derived
from herbs are known to inhibit growth of cancer by modulating the activity of
specific hormones and enzymes. Some herbs reduce toxic side effects of
chemotherapy and radiotherapy. Scientists all over the world are concentrating on
the herbal medicines to boost immune cells of the body against cancer. By
understanding the complex synergistic interaction of various constituents of
anticancer herbs, the herbal formulations can be designed to attack the cancerous
cells without harming normal cells of the body.
Phytoconstituents derived from the herbs have been used in various
formulations to enhance activity of immune cells of the body that promotes
production of cytokines including interleukin, interferon, tumor necrosis factor and
colony stimulating factor. These formulations help the body to fight cancer more
effectively and reduce toxic side effects of chemotherapy and radiotherapy stages of
cancer. (Rajandeep Kaur, et al)
1.11.1 Plant derived anticancer agents in clinical use
The isolation of the vinca alkaloids, vinblastine and vincristine from the
Madagascar periwinkle, Catharanthus roseus G. Don. (Apocynaceae) introduced a
new era of the use of plant material as anticancer agents. They were the first agents
to advance into clinical use for the treatment of cancer. Vinblastine and vincristine
are primarily used in combination with other cancer chemotherapeutic drugs for the
treatment of a variety of cancers, including leukaemia, lymphomas, advanced
testicular cancer, breast and lung cancers, and Kaposi’s sarcoma. The camptothecin
derivatives, topotecan and irinotecan, and etoposide derived from
epipodophyllotoxin are in clinical use all over the world. A number of promising
agents such as flavopiridol, roscovitine, combretastatin, betulinic acid and silvestrol
are in clinical or preclinical development. The discovery of paclitaxel from the bark
of the Pacific Yew, Taxus brevifolia Nutt. (Taxaceae) is another evidence of the
success in natural product drug discovery. Various parts of Taxus brevifolia and
other Taxus species (e.g., Taxus Canadensis Marshall, Taxus baccata L.) have been
used by several Native American Tribes for the treatment of some non-cancerous
cases while Taxus baccata was reported to use in the Indian Ayurvedic medicine for
the treatment of cancer.
1.11.2 Plant derived anticancer agents for future development
Numerous types of bioactive compounds have been isolated from plant
sources. Several of them are currently in clinical trials or preclinical trials or
undergoing further investigation. Flavopiridol is a synthetic flavone, derived from
the plant alkaloid rohitukine, which was isolated from Dysoxylum binectariferum
Hook. F. (Meliaceae). It is currently in phase I and phase II clinical trials against a
broad range of tumors, including leukaemia, lymphomas and solid tumors. Synthetic
agent roscovitine which is derived from natural product olomucine, originally
isolated from Raphanus sativus L. (Brassicaceae), is in Phase II clinical trials in
Europe. Combretastatins were isolated from the bark of the South African tree
Combretum caffrum Kuntze (Combretaceae) Combretastatin A-4 is active against
colon, lung and leukemia cancers and it is expected that this molecule is the most
cytotoxic phytomolecule isolated so far. (Mohammad Shoeb, et al)
1.11.3 Preventing cancer using folk remedies
Medicinal herbs of folk-origin are significant sources of synthetic and herbal
drugs. In the commercial market, folk-medicinal herbs are used as raw drugs,
extracts or tinctures. Isolated active constituents are used for applied research for
finding their bioactivity. For the last few decades, phytochemical examination has
been making rapid progress and herbal products are becoming popular as sources of
plausible anticancer compounds. To facilitate the readers to look at their areas of
interest, we have tried to discuss potential anti cancer photochemical as drugs in this
article. In this review anti-cancer pharmacological investigations of important
phytochemicals for current status have been discussed. In vitro anti cancer studies
have demonstrated that natural products of flavonoid type like luteolin and quercetin
have the power to inhibit the proliferation of cells in human carcinoma of larynx and
sarcoma-180 cell lines.
1.11.4 Natural products from folk medicines which are under trial
or for approval as drugs
Some of the folk medicine described plant-derived secondary metabolites
and their semi synthetic derivatives, are undergoing clinical trials as anticancer
drugs (camptothecin, paclitaxel, epipodophyllotoxin, and vinblastine. In addition,
the phytochemical combretastatin A4, was isolated from the South African
medicinal tree, Combretum caffrum (Combretaceae), was derivatized to
combretastatin A4 phosphate and AVE-8062. These analogs bind to tubulin leading
to morphological changes and then disrupt tumor vasculature, and are in phase II
trials.
1.11.5 Mechanism of some potential active ingredients
Pytochemicals isolated from folk medicines are found to act as potent
antioxidants and free radical scavengers. These natural products are supposed to
minimize DNA damage by reacting with free radicals and in this way they could
prevent cancer. Some of the Pytochemical antioxidants of folk medicines are
inhibitors of lipoxygenase and urokinase. Inhibition of these enzymes by folk
medicines could prevent or reduce cancer growth and in this way their mechanism of
action can be established. Natural products of folk-medicine, for example, genistein
and curcumin, are found to decrease urokinase plasminogen activator thus helping to
fight against cancer. (G. Venkateshwar Rao, et al)
1.11.6 Plants with anticancer activity
Sr.
No.
Botanical
name
Family Common
name
Active constituent
1 Allium sativum Liliaceae Garlic Alliin ,allicin alliin, alliinase,
S-allylcysteine
(SAC), diallyldisulphide
,(DADS), diallyltrisulphide
(DATS) and
methylallyltrisuphide.
2 Actinidia
chinensis
Actinidiaceae China
gooseberry,
Kiwifruit
Polysaccharide known as
“ACPS-R”
3 Aloe ferox,
Aloe
barbadenis
Liliaceae Aloe vera Aloe-emodin, emodin,  aloin
acemannan,
4 Ananas
comosus
Bromeliaceae Pine apple,
Ananas
Bromelain
5 Angelica
sinensis
Umbelliferae Angelica Polysaccharide fraction of
known as “AR-4”
6 Annona species Annonaceae Monkey
species
Acetogenins
7 Arctium lappa, Compositae Burdock Potent anticancer factors.
8 Astragalus
membranaceus
Papilionaceae --- Swainsonine
9 Betula utilis Betulaceae Bhojpatra Betulin
10 Camellia
sinensis
Theaceae Tea plant Epigallocatechin gallate
11 Catharanthus
roseus
Apocynaceae Vinca Vinblastine, Vincristine ,
Alstonine,
Ajmalicine and Reserpine.
12 Chlorella
pyrenoidosa
Oocystaceae --- Lysine
13 Colchicum
luteum
Liliaceae Colchicum Colchicines demecolcine
14 Combretum
caffrum
Combritaceae --- Combretastatin
15 Curcuma longa
Linn.
Zinziberaceae Turmeric Tumerone, curcumine
16 Echinacea
angustifolia
Asteraceae Black
Sampson
Arabinogalactan,
Jucogalactoxyloglucans.
17 Fagopyrum
esculentum
Polygonaceae Vitamin p Amygdalin, Rutin
18 Ginkgo biloba Ginkoaceae Kew tree Ginkgolide-B, A, C and J
19 Glycyrrhiza
glabra
Leguminosae Liquorice Glycyrrhizin.
20 Gossypium
barbadense
Malvaceae Raw cotton Gossypol
21 Gyrophora
esculenta
Umbilicariaceae Mushroom Polysaccharides ß-glucans, a-
glucans,
and galactomannans.
22 Linum
usitatissimum
Linaceae Flax seed,
Linseed
Cynogenetic glycosides,
Lignans
23 Mentha species Labiateae Pudina Monoterpene ketones
24 Panax ginseng Aralaceae Ginseng Ginsenosides, Panaxosides
25 Picrorrhizia
kurroa
Scrophulariaceae Picrorrhizia
(kutki)
Picrosides I, II, III and
kutkoside
26 Podophyllum
hexandrum
Berberidaceae Podophyllum Podophyllin,astragalin
Table No. 1.3 Plants with anticancer activity (D.M Sakarkar, et al)
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2.1 Plant Profile
Fig. 2.1 Chromolaena odorata leaves
2.1.1 Classification of the plant
Kingdom Plantae
Subkingdom Tracheobionta
Supervision Spermatophyte
Division Magniliprida
Class Magnoliprida
Subclass Astride
Order Asterales
Family Asteraceae
Genus Chromolaena Dc
Species Chromolaena odorata (L) King & Robins.
Synonyms Eupatorium odoratum L,
Eupatorium conyzoides Vahl,
Eupatorium brachiatum Sw. ex Wikstr,
Eupatorium atriplicifolium Vahl,
Osmia odorata (L.) Schultz-Bip.
Vernacular Name : English- Siam weed, Christmass bush
Tamil- Kambila
Hindi- Bagh dhoka
Malayalam - Communist pacha
Family : Asteraceae ( Compositae )
2.1.2 Introduction
Chromolaena odorata is an aggressive species of perennial weed and
belonging to the family Asteraceae, which widely occurs in the plantations of South
India. (G.O. Adesine, et al)
It is fast growing oppressive, competitive occupying different kinds of arable
land by forming dense strands that tends to prevent the growth of other flora.
Therefore if affects plantation and other organisms in the ecosystem by its
suppressive effects to young [plants as it is a growth inhibitor and has allelopathic
capabilities. A lot of pharmacological and medicinal effects of extracts of
Chromolaena odorata showed traditional uses of the plant especially in Asia to cure
various disease ailments.  Traditionally, boil fresh leaves of the plant has been used
in many countries for treating various skin diseases. The leaf poultices of the plant
were used in the treatment of fresh wounds and as an aid to stop bleeding. Its root
can be used as analgesic and antipyretic. The extract of the leaves could be as gargle
for treatment of sore throat and flu. One significant agronomic properties of the
plant is that can be propagate either by seed or stem, but propagation by cutting is
preferred mostly. (W. Orapa, et al)
2.1.3 General Description
Chromolaena Odorata is also known as Christmas bush, Bitter bush, Siam
weed, Baby tea, Cariaquillo, and Santa Maria. It is a scrambling shrub. The plants
have abundant, yellowish, fine lateral roots. Multiple sprouts arise from the root
crown and lower stems. Individual branches are long with relatively few branches.
The opposite, three-nerved leaves are deltoid to ovate lanciolate, usually with a
dentate margin and a long pointed tip. The leaves are aromatic when crushed. The
inflorescences are corymbs of cylindrical heads located on the terminals of lateral
branches. There are 15 to 20 tubular florets per head, white, lavender, pink or blue in
colour. The seeds are a brownish gray to black that is 4 mm long with a pale brown
pappus 5 or 6 mm long. (C. Zacharaides, et al)
Leaves
The leaves are soft, green, hairy and triangular in shape, with a distinctive
three-vein (pitch fork) pattern. New growth exhibits a purple colouration. The stems
are smooth, round and hairy brittle, becoming woody at the base when old.
Flowers
Flowers bloom from May to July again in September to October, producing
masses of pale lilac flowers that appear white from a distance. They turn a darker
lilac when matured.
Seeds
The plane produces huge numbers of windborne seeds within 8-10 weeks
after flowering. Each seeds have a tuft of white hairs that allowed it to be
transported by wind and water. Most seeds germinate immediately after rain, though
some appear to remain dormant for several years. (Warea Orapa, et al)
Uses
 Fresh leaves or decoction have been used for the treatment of leech bite, soft
tissue wounds, burn wound and skin infection.
 The leaf poultices of the plant were used in the treatment of fresh wounds
and as an aid to stop bleeding.
 Root can be used as analgesic and antipyretic.
 The extract of the leaves could be as gargle for treatment of sore throat and
flu.
 Macerated leaves are usually applied to swollen portion of the body to
relieve inflammation.
2.2 Literature Review
Afolabi C. Akinmoladun et al., 2007 reported “Phytochemical constituent and
antioxidant properties of Chromolaena odorata Linn”
“The author reported that aqueous and methanolic extracts of Chromolaena
odorata were screened for phytochemical constituents. Tannins, steroids, terpenoids,
flavonoids and cardiac glycosides were present in both the extract. Alkaloids were
detected only in the methanolic extract. Antioxidant activity of Chromolaena
odorata was performed and compared with standards (gallic acid and ascorbic acid).
Results showed that percentage antioxidant activity of Chromolaena odorata is
about one third of the value for gallic acid and ascorbic acid”.
Alisi CS et al., 2011 reported “Antimicrobial action of methanol extract of
Chromolaena odorata Linn”
“The author reported that the plant Chromolaena odorata contain flavonoids,
tannins, saponins, glycosides, steroidal aglycones, alkaloids and 4-hydroxybenzoic
acid. But methanol extract did not show positive reactions for saponins.
Antimicrobial activity of Chromolaena odorata was performed and showed that
methanol extract of Chromolaena odorata inhibited dehydrogenase activity in the
organisms in a logistic dose dependant manner”.
Alisi, C. S et al., 2008 reported “Nitric oxide scavenging ability of ethyl acetate
fraction of methanolic leaf extracts of Chromolaena odorata Linn”
“The author reported the concentrating effect of ethyl acetate on plant
phenolic compound. Nitric oxide scavenging ability of ethyl acetate fraction of
methanolic extracts of Chromolaena odorata was performed. Results exhibited that
ethyl acetate fraction demonstrated a marked ability to scavenge nitric oxide and/or
inhibit nitrite formation. The ethyl acetate fraction of Chromolaena odoratat ability
to scavenge nitric oxide generated in vitro by sodium nitroprusside was
concentration dependent”.
Anyasor, G.N et al., 2011 reported “Phytochemical constituent, proximate analysis,
antioxidant, antibacterial and wound healing properties of leaf extracts of
Chromolaena odorata Linn”
“The author reported that, the aqueous and ethanolic leaf extracts of
Chromolaena odorata indicated the presence of saponins, phenols and tannins.
Phlobatannins and alkaloids were present in the aqueous extract while cardiac
glycosides, anthraquinones and terpenoids were present in the ethanolic extract.
Proximate analysis showed that Chromolaena odorata could serve as a good source
of energy, flavour, minerals, protein and dietary fibre. Antioxidant assays and
antibacterial studies of the plant extract were performed. Results exhibited that
Chromolaena odorata shows good antioxidant and antibacterial action”.
Bamidele Victor Owoyele et al., 2008 reported “Analgesics, anti-inflammatory and
antipyretic activities from flavonoid fractions of Chromolaena odorata Linn”
The author reported that crude ethanolic extract of Chromolaena odorata
was fractionated using water and four solvents- n-hexane, dichloromethane, ethyl
acetate and           n-butanol. Pytochemical screening, analgesics, anti-inflammatory
and antipyretic activity of all the fractions were performed. Results exhibited that the
active constituent responsible for analgesi, anti-inflammatory and antipyretic
activities of Chromolaena odorata are mainly flavonoid compounds”.
C. S. Alisi et al., 2011 reported “Normalisation of Lipoproteins Phenotypes by
Chromolaena odorata Linn”
“The author reported that ethanolic extract of Chromolaena odorata has got
the ability to prevent dyslipidemia resulted from carbon tetrachloride induced
oxidative damage. Mechanism of action is not fully understood but the protection
conferred on the liver by the extract would have preserved the liver cell to function
in the maintenance of lipoprotein phenotype. Intake of Chromolaena odorata extract
in diet may offer useful benefit in the preservation of lipoprotein phenotype, which
will also be beneficial in the reduction of cardiovascular risk associated with
dyslipidemia”.
Debashisha Panda et al., 2010 reported “Phytochemical analysis and investigation
of anthelmentic and wound healing potentials of Chromolaena odorata Linn”
The author reported that petroleum ether, ethyl acetate and methanol extracts
were analyzed for different phytoconstituents by the method of qualitative
phytochemical analysis. Anthelmentic activity of different extracts of Chromolaena
odorata was performed. Results exhibited that methanol extract showed potent
anthelmentic activity when compared to petroleum ether and ethyl acetate extracts.
In wound healing activity methanolic extract was endowed with potent wound
healing property when compared to petroleum ether and ethyl acetate extracts”.
G. Bedi et al., 2010 reported “Effect of essential oil of Chromolaena odorata Linn”
“The author reported that essential oil of Chromolaena odorata was obtained
by using Clevenger apparatus. Cyclooxygenase function of prostaglandin-H
synthase activity of essential oil of Chromolaena odorata was performed. Results
showed that essential oil of Chromolaena odorata increased the activity of
cyclooxygenase function of prostaglandin-H synthase. The concentration value of
essential oil required to increase the activity of the cyclooxygenase function of
prostaglandin-H synthase was found to be 87.5µg/ml”.
Igboh M. Ngozi et al., 2009 reported “Chemical profile of Chromolaena odorata
Linn”
“The author reported the proximate composition of Chromolaena odorata.
This indicates that Chromolaena odorata may have a short shelf life due to its high
moisture content. Phytochemical screening was carried out and results showed that
Chromolaena odorata is highly rich in saponins, moderately rich in phytates and
tannins, with little content of alkaloids, flavonoids and cyanogenic glycosides”.
K. K. Naidoo et al., 2011 reported “Screening of Chromolaena odorata Linn for
antibacterial and antifungal properties”
“The author reported that, various extracts of leaves of Chromolaena odorata
inhibited several gram positive and gram negative bacteria. All gram positive
bacteria were inhibited by the ethyl acetate extracts obtained from the leaves, except
for S. aureus and methanol extracts derived from the leaves inhibited all gram
positive bacteria including one gram negative bacteria, E.coli. Antifungal and
antimicrobial activity of ethanol and aqueous extract of the plant was performed.
Results exhibited that ethanol extract was found to be more effective than aqueous
extracts in the leaf and stem extracts”.
Moses S. Owolabi et al., 2010 reported “Chemical composition and bioactivity of
the essential oil of Chromolaena odorata Linn”
“The author reported that essential oil of Chromolaena odorata obtained by
using Clevenger apparatus was light green oil. GC-MS analysis of the essential oil
was carried out and led to the identification of 56 components, representing 99.3%
of the oil. The oil was found to be rich in α and β-pinenes, germacrene D, β-copaene
and caryophyllene. Antimicrobial screening of the essential oil of Chromolaena
odorata was performed and showed to exhibit marginal antibacterial activity against
Bacillus cereus and antifungal activity against Aspergillus niger”.
Pierangeli G. Vital et al., 2009 reported “Antimicrobial activity and cytotoxicity of
Chromolaena odorata Linn”
The author reported antimicrobial and cytotoxic properties of ethanol
extracts of leaves of Chromolaena odorata and ethyl acetate extracts of stem bark of
Uncaria perrottetii. The ethanolic extract of Chromolaena odorata leaves showed
antimicrobial activity against B.subtilis, S. aureus and S. typhimurium.
Phytochemical screening tests were also carried out and results exhibited that
Chromolaena odorata showed the presence of flavonoids, saponins, tannins and
steroids and Uncaria perrottetii showed the presence of alkaloids, tannins and
leucoanthocyanin.
Rajmohon D et al., 2011 reported “Insecticidal properties of Chromolaena odorata
Linn against the life cycle of the mosquito, Aedes aegypti”
“The author reported that, acetone extract of the leaves of Chromolaena
odorata showed low percentage of egg hatchability and high percentage of larval
and pupal mortality. Results indicated that biomass of Chromolaena odorata can be
used as repellent to control mosquito population”.
Tran Manh Hung et al., 2011 reported “Flavonoid Glycosides from Chromolaena
odorata Linn leaves and in vitro Cytotoxic Activity”
“The author reported that, ethyl acetate soluble fractions of the 70%
ethanolic extract of Chromolaena odorata resulted in the purification of thirteen
compounds. The known compounds were identified as aromadendrin 4' methyl
ether, eriodictyol 7, 4'-dimethy ether, 4' –methyl ether, isosakuranetin, quercetin 7,
4'-dimethy ether, kaempferide, acacetin, rhamnazin, quercetin 3-O-rutinoside,
kaempferol 3-O-rutinoside and kaempferol 3-O-glucopside. Cytotoxic activity of
ethanol extract of Chromolaena odorata was performed. Results showed significant
cytotoxic activity in the inhibition of HL-60 cancer cell lines”.
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AIM AND SCOPE OF WORK
In India, drugs of herbal origin have been used in traditional system of
medicine such as Ayurveda, Unani and Homeopathy since ancient times. Most
common traditional system in India is Ayurveda and Homeopathic systems. Public
seems to be fed up with modern medicine (synthetic drugs) mainly due to only
symptomatic relief is experienced, completion of treatment is never a reality, more
so in chronic ailments, frustrating side effects and high cost involved. The general
opinion of the public is moving towards use of herbal drugs. This is due to the
reason that Ayurveda is considered to be our own system and it relies only on
natural remedies and reasons for homeopathy finding favours are its ease of
administration of dose, high acceptability by children and no side effects (Sunil
Jawla, et al).
Keeping above in mind, this study was conducted. The aim of the present
study is to find out new anticancer substances from the indigenous plant,
Chromolaena odorata Linn. (Asteraceae) a traditional medicinal plant consisting a
wide range of pharmacological, biological activities and phytochemical constituents.
Literature survey revealed that some amount of pharmacological work has been
carried out on Chromolaena odorata such as anthelmentic, wound healing,
antioxidants, antimicrobial, analgesics, antifungal and antibacterial activity. But no
work has been found during literature survey in line of anticancer activity. Therefore
it was thought worthwhile to carry out preliminary phytochemical screening,
characterisation of the isolated ingredients by means of spectral studies and
pharmacological investigation in line of anticancer activity. The selection of the
plant was made on the basis of its availability, therapeutic value and the lesser
degree of research work with reference to the said pharmacological aspects.
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The research work entitiled “Phytochemical Characterization and in vitro
anticancer screening of ethanol extract of Chromolaena odorata Linn” was carried
with the following aspects.
Part 1: Phytochemical studies
 Collection and authentication of plant material.
 Solvent extraction of plant material with petroleum ether (60-80 °C).
 Solvent extraction of plant material with ethanol (95% v/v).
 Preliminary phytochemical screening of both extracts.
 Thin layer chromatography of the extracts.
 Isolation of plant constituent by column chromatography.
 Characterization of isolated compound by spectral studies.
Part 2: Pharmacological studies
In vitro studies
 Evaluation of anticancer activity of the ethanol extract by MTT assay
using human colorectal adenocarcinoma cell line (HCT116) and human
cervical cancer cell lines (HeLa).
CHAPTER-5
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5.1 Phytochemical Studies
Collection and authentication of plant
The leaves of plant Chromolaena odorata Linn (Asteraceae) was collected in
the month of July 2011 from Perur, near Perur temple, Coimbatore, Tamilnadu and
was authentified by Dr. M. Palanisamy, Scientist ‘C’ with reference number of
No.BSI/SRC/5/23/2010-11/Tech.1089. Botanical Survey of India, Southern
Regional Centre, Coimbatore – 641 003.
Preparation of plant sample
The collected leaves of Chromolaena odorata were dried under shade and
using a mechanical grinder it was made into a coarse powder. The powder was
passed through sieve No.40 and packed in thimble and stored for further use.
Extract procedure
The dried coarse powder material of Chromolaena odorata leaves (150gm)
was deffatted with petroleum ether (60-80 °C) in a soxhlet apparatus and extraction
was continued for 72 hours to remove waxy substances, which usually interfere in
the isolation of phytoconstituents. Then the marc after defatted with petroleum ether
was dried and extracted with ethanol (95% v/v) in a soxhlet apparatus. The solvent
was then distilled off and the resulting semisolid mass was dried in a dessicator and
the mass obtained was weighed.
Plant material (leaves)
Dried under shade and made into coarse powder
Powder passed through seive No. 40
150 gm of powdered leaves packed in a thimble
Defatted with petroleum ether (60-80 °C) on soxhlet apparatus for 72 hours
(A) to remove waxy substances
Marc (A) dried and extracted with ethanol (95% v/v) on soxhlet apparatus for 72
hours
Solvent distilled off
Semisolid mass dried in desiccator.
Chart. 5.1 Diagrammatic representation of extraction procedure
5.2 Preliminary phytochemical screening
The petroleum ether and ethanol extracts of Chromolaena odorata were
subjected to qualitative test for the identification of various chemical constituents.
5.2.1 Test for alkaloids
Small amount of extract was treated with few drops of dilute hydrochloric
acid and filtered. The filtrate was collected and subjected for following tests.
A. Mayer’s Test: (Potassium Mercuric Iodide)
1 ml of the extract was added with 1 ml of Mayer’s reagent (potassium
mercuric iodide solution). Whitish yellow coloured precipitate indicated the
presence of alkaloids.
B. Dragendroff’s Test: (Potassium Bismuth Iodide)
To 1 ml of the sample solution 2 ml of Dragendroff’s reagent was added.
Formation of orange red precipitate indicated the presence of alkaloids.
C. Wagner’s Test: (Iodide in Potassium Iodide)
Fraction of the extract was treated with 2 ml of Wagner’s reagent and
observed for the formation of reddish brown coloured precipitate.
D. Hager’s Test: (Picric Acid)
Fraction of the extract was treated with Hager’s reagent and observed for the
formation of yellow coloured precipitate. (Surekha, et al)
5.2.2 Test for carbohydrates
A. Molisch’s Test
1 ml of filtrate was mixed with 2 drops of Molish’s reagent and 1 ml of
concentrated sulphuric acid was added along the sides of the test tube. Brown to
violet ring indicates the presence of carbohydrates. (C.K. Kokate, et al)
B. Fehling’s Test
Extract was treated with Fehling’s solution A and B and heated on a water
bath for few minutes and observed for the formation of red precipitate of cuprous
oxide.
C. Barfoed’s Test
Small portion of the extract was treated with Barfoed’s reagent and observed
for the formation of red precipitate.
D. Benedict’s Test
Small portion of the extract was treated with Benedict’s reagent and placed
in boiling water bath for few minutes and observed for the formation of orange red
precipitate. (G A Ayoola, et al)
5.2.3 Test for glycosides
A. Legal’s Test
To the sample, 1ml pyridine and few drops of sodiumnitroprusside solution
were added and then it was made alkaline with sodium hydroxide solution.
Appearance of pink to red colour indicates the presence of glycoside.
B. Keller Killani Test
1 gm of powdered drug was extracted with 10 ml of 70 % alcohol for few
minutes and filtered. To 5 ml of filtrate, 10 ml of hydrogen peroxide and 0.5ml of
strong solution of lead acetate were added. The precipitate thus obtained was
filtered. Filtrate was shaken with 5ml of chloroform and the layer was separated and
to this 1ml of mixture, 1 volume of 5 % ferric sulphate and 99 volumes of glacial
acetic acid were added.
To this mixture 1 or 2 drops of conc. Sulphuric acid was added. Appearance
of blue colour confirmed the pressure of de oxy sugars.
C. Borntrager’s Test
The extract was treated with chloroform and the chloroform layer was
separated. To this equal quantity of dilute ammonia solution was added. Ammonia
layer acquired rose pink colour indicates the presence of glycoside.
5.2.4 Test for fixed oil and fats
A. Stain test
Small quantity of the extract was separately passed between two filter
papers. Appearance of stain on the paper indicates the presence of fixed oil.
B. Saponification Test
Few drops of 0.5 alcoholic potassium hydroxide was added to a small
quantity of extract along with a drop of Phenolphthalein. The mixture was heated on
water bath for 1-2 hours formation of soap neutralization of alkali indicated the
presence of fixed oil and fats.
5.2.5 Test for tannins and phenolic compounds
A. Ferric Chloride Test
To the small quantity of extract few drops of 5% ferric chloride solution was
added. Formation of brownish colour indicated the presence of phenolic compounds.
B. Lead acetate Test
To the extract, 10% of lead acetate solution was added. Formation of white
precipitate indicated the presence of tannins.
C. Gelatin Solution Test
To the extract 1% solution of gelatin containing sodium chloride solution
was added and observed for the formation of white precipitate.
D. Potassium dichromate test
5ml of filtrate was treated with 1ml of 10% aqueous potassium dichromate
solution. If yellowish- brown precipitate was formed it suggested the presence of
tannins. (K.R. Khandelwal, et al)
5.2.5 Test for triteprenoids
A. Salkowsky Test
A small quantity of extract was treated with 5ml of concentrated sulphuric
acid, the solution turned yellow to red, indicated the presence of triterpenoids.
B. Liebermann – Burchard Test
A small quantity of extract was treated with 0.2ml concentrated sulphuric
acid and 4ml acetic anhydride. The solution turned pink in colour and finally
becomes purple showing the presence of triterpenoids.
5.2.6 Test for saponins
A. Foam Test
The extract was diluted with 20ml of distilled water and it was agitated on a
graduated cylinder for 15 minutes. The formation of 1cm layer of foam showed the
presence of saponins. (C.K. Kokate, et al)
5.2.7 Test for proteins
A. Millions Test
To the extract, little of water and Millon’s reagent was added. Appearance of
red colour showed the presence of proteins.
B. Ninhydrin Test
To the extract little of ninhydrin reagent was added. Appearance of purple
colour showed the presence of proteins.
C. Biuret test
1ml of filtrate was taken in water and 1mnl of 4% copper sulphate was added
to it, violet or pink colour is formed, indicates the presence of proteins. (K.R.
Khandelwal, et al)
5.2.8 Test for flavones & flavonoids
A. Aqueous Sodium hydroxide test
To small amount of sample solution add aqueous sodium hydroxide solution.
Formation of rellow colour indicates the presence of flavonoids.
B. Concentrated Sulphuric acid Test
To small amount of sample solution add 5 ml of dilute ammonia and 1 ml of
concentrated sulphuric acid. Formation of yellow colour indicates the presence of
flavonoids. (G A Ayoola, et al)
C. Schinodo’s Test
To a small fraction of the extract add few magnesium turnings followed by
concentrated hydrochloric acid and then slightly boiled. Red colour formation
indicates the presence of flavonoids. (K.R. Khandelwal, et al)
5.3 Chromatographic studies
Introduction
Chromatography was introduced first by the Russian botanist Micharl Iswett.
It is a method for separating the components of a mixture by differential distribution
of the components of the mixture between a stationary phase and a mobile phase.
Chromatography was initially used for the separation of coloured substances from
the plants, but today it has become the most extensive technique of separation and
purification of organic compounds.
The basic principle of separation is the difference in the affinity of the
different compounds to stationary phase. They are then flushed through the system
at different rates. These differential rates of migration as the mixture moves over
adsorptive materials provide separation. Repeated sorption or desorption that take
place during the movement of the sample over the stationary phase determines the
rates. Thus, smaller the affinity a molecule has for the stationary phase, the shorter
the time spent in a column. (Geetu Gambhir, et al)
5.3.1 Thin layer chromatography (TLC)
Thin layer chromatography is an important analytical tool in separation,
identification and estimation of different components. It is a solid-liquid form of
chromatography where the stationary phase is normally a polar adsorbent and the
mobile phase can be a single solvent or combination of solvents. Thin layer
chromatography is a quick, inexpensive micro scale technique that can be used to
determine the number of components in a mixture. (A.V Kasture, et al)
General techniques in TLC
 Preparation of thin, uniform layer plate with adsorbent
 Activation of TLC plates
 Application of sample on TLC plates
 Selection of solvent system
 Separation chamber and development
 Detecting agents or visualizing agents
 Determination of Rf values (Egon Stahl, et al)
Procedure
 Required quantity of silica gel G was taken.
 Sufficient quantity of distilled water was added and mixed to produce slurry.
 The slurry was then poured into TLC plates by spreading technique to
obtained uniform layer.
 The coated plates were allowed to dry in air and activated by heating in hot
air oven at 100 °C for 1 hour.
 With the help of capillary tube the prepared extract previously dissolved in
respective solvent was spotted about 1 cm from one end of the TLC plate.
 The plate was then placed in the development tank previously saturated by
the mobile phase.
 This mobile phase rises by the capillary action through the plate.
 Development was continued till the solvent front reaches 3/4th of the plate.
 The plate is removed from the chamber and the solvent front is marked.
 The plate is kept for air drying and detecting agent or visualizing agent is
applied.
 Rf value of the spots are recorded and are used for qualitative identification
of the compounds. (Kasture A V, et al)
Measurement of Retention factor (Rf)
The migration distances of substances on thin layer chromatograms are
generally fixed as Rf values. It is called as retention factor and is calculated as
follows.
Distance travelled by solute
Rf = --------------------------------------------
Distance travelled by the solvent front
The Rf values depend on solvent system, adsorbent and amount of material
spotted etc. (JB Harborne, et al)
5.3.2 Column chromatography
Column chromatography is also known as adsorption chromatography. The
mixture to be separated is dissolved in a suitable solvent and allowed to pass through
a tube containing the adsorbent. The component which has greater absorbing power
is adsorbed in the upper part of the column. The next component is adsorbed in the
lower portion of the column which has lesser adsorbing power than the first
component. This process is continued. As a result the materials are partially
separated and adsorbed in the various parts of the column. The initial separation of
the various can be improved by passing either the original or some other suitable
solvent slowly through the columns. The various bands present in the column
become more defined. The banded column of the adsorbent is termed as
chromatogram, and the operation is known as development of chromatogram. The
portion of a column which is occupied by a particular substance is called its zone.
The narrower the zones, the longer the number of substances which can be separated
in a column of a definite length, and the more concentrated are the eluates. (Gurdeep
R. Chatwal et al)
Fig. 5.2 Column chromatography of ethanol extract of Chromolaena odorata
Materials and method
Adsorbent – Silica gel for column chromatography
Activation – 110 °C for 1 hour
Mobile phase – Petroleum ether, Benzene, Chloroform and Methanol
Quantity of extract – 4 grams
Extract used – Ethanol extract of Chromolaena odorata leaves
Length of column – 60 cm
Diameter of column – 2.5 cm
Rate of elution – 20 drops per minute
Volume of fraction – 20 ml each
Method of packing – Wet packing
Technique – Gradient elution
Procedure
Packing a silica gel column
 Column was taken, washed and rinsed water and petroleum ether and made
to dry completely.
 After complete drying, a small piece of cotton wool was placed in the bottom
of the column followed by whatmann filter paper.
 Then the column was filled with silica gel previously activated at 110 °C for
1 hour.
 Sufficient amount of solvent was made to run in order to make the silica gel
completely settled.
 Once silica gel has settled, two whatmann filter papers were added carefully
to the top of the column.
Loading a sample into the column
 4 gm of extract was taken in a china dish and mixed with silica gel.
 The mixture was then stirred well until it forms a free flowing powder.
 The sample was then packed into the column with the help of a clean dry
funnel.
 Two whatmann filters are then placed on to the top of the sample layer.
 Then a small piece of cotton wool is placed on to the top of whatmann filter
paper.
Eluting the sample
 The column was eluted by gradient method in increasing polarity (petroleum
ether, benzene, chloroform and methanol).
 The fractions were then collected in clean 100 ml labelled boiling tube up to
20 ml with the speed of 20 drops per minute.
Analysing the fractions
The collected fractions were analysed by thin layer chromatography to
determine if the fractions contains more than one component and if the fractions can
be combined. The Phytochemical tests were then performed as to confirm which
phytoconstituent is present in the fraction. The fractions containing the similar Rf
values were combined together. The collected fractions were made to dry and is
used for spectral studies using UV, IR and NMR etc.
5.4 Pharmacological Screening
Materials
The human colorectal adenocarcinoma cell line (HCT116) and human
cervical cancer cell line (HeLa) was obtained from National Centre for Cell Sciences
(NCCS), Pune. The HCT116 cells were grown in Dulbeccos modified eagles
medium (DMEM) and HeLa cells were grown in Eagles minimum essential medium
(EMEM) containing 10% fetal bovine serum (FBS). All cells were maintained at 37
°C, 5% CO2, 95% air and 100% relative humidity. Maintenance cultures were
passages weekly, and the culture medium was changed twice a week. (Monks A, et
al and Mosmann T, et al)
Cell treatment procedure
The monolayer cells were detached with trypsin-ethylenediaminetetraacetic
acid  (EDTA) to make single cell suspensions and viable cells were counted using a
haemocytometer and diluted with medium with 5% fetal bovine serum (FBS) to give
final density of 1×105 cells/ml. one hundred micro litres per well  of cell suspension
were seeded into 96-well plates at plating density of 10,000 cells/well and incubated
to allow for cell attachment at 37 °C, 5% CO2, 95% air and 100% relative humidity.
After 24 hours, the cell were treated with serial concentrations of the extracts and
fractions. They were initially dissolved in neat dimethysulfoxide (DMSO) and
further diluted in serum free medium to produce five concentrations. One hundred
microlitres per well of each concentration was added to plates to abtain final
concentrations of 500, 250, 125, 62.5 and 31.25 µg/ml respectively. The final
volume in each well was 200 µl and the plates were incubated at       37 °C, 5% CO2,
95% air and 100% relative humidity for 48 hours. The minimum containing without
samples were served as control. Triplicate was maintained for all concentrations.
MTT Assay
Measurement of cell viability and proliferation forms the basis for numerous
in vitro assays of a cell population in response to external factors. The reduction of
tetrazolium salt is now widely accepted as a reliable way to examine cell
proliferation. The yellow tetrazolium MTT (3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide) is reduced by metabolically active cells, in part by the
action of dehydrogenase enzymes, to generate reducing equivalents such as NADH
and NADPH. The resulting intracellular purple formazan can be solubilised and
quantified by spectrophometric means.
The MTT cell proliferation assay measures the cell proliferation and
conversely, when metabolic event leads to apoptosis or necrosis, the reduction in
cell viability. The MTT reagent yields low background absorbance values in the
absence of cells. For each cell type the linear relationship between cell number and
signal produced is established, thus allowing an accurate quantification of changes
in the rate of cell proliferation. (American type culture collection, 2001)
Principle
MTT is a yellow soluble tetrazolium salt. A mitochondrial enzyme in living
cells, succinate-dehydrogenase, cleaves the tetrazolium ring, converting the MTT to
an insoluble purple formazan. Therefore, the amount of formazan produced is
directly proportional to the number of viable cells.
After 48 hours of incubation, 15 µl of MTT (5mg/ml) in phosphate buffered
saline (PBS) was added to each well and incubated at 37 °C for 4 hours. The
medium with MTT was then flicked off and the formed formazan crystals were
solubilised in 100 µl of DMSO (dimethyl sulfoxide) and then measured the
absorbance at 570 nm using micro plate reader. The percentage cell inhibition was
determined using the following formula.
Percentage (%) cell inhibition = 100-Absorption (sample)/Absorption (control) ×
100.
Nonlinear regression graph was plotted between percentahe cell inhibition
and Log10 concentration and IC50 was determined using Graphpad Prism software.
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6.1 Preliminary phytochemical screening of Chromolaena odorata
extracts
Extraction of Chromolaena odorata
Dried crushed leaves of Chromolaena odorata was used for extraction by pet
ether (60-80 °C) and ethanol (95% v/v) and the results are tabulated in Table No.
6.1.1.
Plant name Part used Extraction
method
%w/w yield
Chromolaena
odorata
Leaves Continuous hot
percolation
process
Petroleum ether
(60-80 °C)
Methanol
(95%v/v)
0.75 5.80
Table No. 6.1.1 Data showing the extractive values of leaves of Chromolaena
odorata
Preliminary phytochemical screening
The extracts of Chromolaena odorat were used for preliminary
phytochemical screening such as alkaloids, flavonoids, phytosterols, glycosides,
saponons, terpenoids and tannins etc as per the procedure discussed in topic 5.2 of
chapter 5. The results are tabulated in Table No. 6.1.2. The extract shows the
presence of alkaloids, flavonoids, glycosides, triterpenoids, tannins and phenolic
acid, carbohydrates and proteins.
Sr.
No.
Chemical Test Petroleum ether
Extract
Ethanolic
Extract
1. ALKALOIDS
a. Mayer’s Test + +
b. Dragendroff’s Test + +
c. Wagner’s Test + +
d. Hager’s Test + +
2. CARBOHYDRATES
a. Molisch’s Test - +
b. Fehlings Test - +
c. Barfoed’s Test - +
d. Benedicts Test - +
3. GLYCOSIDES
a. Legal Test - +
b. Kiddes Test - +
c. Born Tragers Test - +
4. FIXED OIL & FAT
a. Stain Test - -
b. Saponification Test - -
5. TANINS & PHENOLICS
a. Ferric Chloride Test - +
b. Lead Acetate Test - +
c. Gelatin Solution Test - +
6. TRITERPENOIDS
a. Salkowsky Test + +
b. Libermann Burchard Test + +
7. SAPONINS
a. Foam Test - -
8. PROTEINS
a. Million’s Test - +
b. Ninhydrin Test - +
Table No. 6.1.2 Qualitative phtytochemical screening results of Chromolaena
odorata
9. FLAVONS &
FLAVONOIDS
a. Aqueous NaOH test - +
b. Conc.Sulphuric Acid Test - +
c. Schinodo’s Test - +
6.2 Thin Layer Chromatography (TLC)
The ethanolic extract of Chromolaena odorata was subjected for TLC by
using various solvent systems. On the basis of trial and error method, the following
solvent system showed 2 to 4 different spots with different Rf values on
development. The results are tabulated in Table No. 6.2.
Solvent system No. of
spots
Colour of
spots
Detecting  agent Rf
value
Toluene : Ethyl acetate (5:5) 2 Green
Green
Iodine chamber 0.72
0.88
Ethyl acetate : Methanol (3:7) 1 Brown Iodine chamber 0.89
Ethyl acetate : Methanol (4:2) 4 Brown
Brown
Brown
Brown
p-toluenesulphuric
acid
0.42
0.57
0.71
0.96
Toluene : Chloroform Acetone
(4:2.5:3.5)
1 Green p-toluenesulphuric
acid
0.73
Benzene : Ethyl acetate (7.5:2.5) 2 Brown
Brown
Iodine chamber 0.59
0.72
Benzene : Ethyl acetate : Diethyl
amine (7:2:1)
3 Brown
Brown
Brown
Iodine chamber 0.29
0.65
0.78
Table No. 6.2 TLC pattern of ethanol extract of Chromolaena odorata
The TLC study was carried out and reported as per the procedure described
in topic 5.3.1 of chapter 5. From the TLC study of the ethanol extract of
Chromolaena odorata showed the presence of four spots as the maximum number of
spots with solvent system Ethyl acetate : Methanol (4:2) using p-toluenesulphuric
acid as detecting agent. The Rf values of the spots were calculated and found to be
0.42, 0.57, 0.71 and 0.96 respectively.
6.3 Column Chromatography
Details of column chromatography of ethanol extract of Chromolaena odorata
Sr.
No.
Frac-
tions Eluent Ratio
Nature of
residue
No of
spot
in
TLC
Rf value TLC eluting
solvent system
1 1-4 Pet. Ether 100 Colourless -- -- Ethyl acetate :
Methanol
2 5-8 Pet. Ether :
Benzene
9 : 1 Colourless -- -- Ethyl acetate :
Methanol
3 9-12 Pet. Ether :
Benzene
8: 2 Colourless -- -- Ethyl acetate :
Methanol
4 13-16 Pet. Ether :
Benzene
7 : 3 Colourless -- -- Ethyl acetate :
Methanol
5 17-20 Pet. Ether :
Benzene
6 : 4 Colourless -- -- Ethyl acetate :
Methanol
6 21-24 Pet. Ether :
Benzene
5 : 5 Colourless -- -- Ethyl acetate :
Methanol
7 25-28 Pet. Ether :
Benzene
4 : 6 Colourless -- -- Ethyl acetate :
Methanol
8 29-32 Pet. Ether :
Benzene
3 : 7 Colourless -- -- Ethyl acetate :
Methanol
9 33-36 Pet. Ether :
Benzene
2 : 8 Colourless Ethyl acetate :
Methanol
10 37-40 Pet. Ether :
Benzene
1 : 9 Colourless -- -- Ethyl acetate :
Methanol
11 41-44 Benzene 100 Colourless -- -- Ethyl acetate :
Methanol
12 45-48 Benzene :
Chloroform
9 : 1 Light
green
colour
1 0.90 Ethyl acetate :
Methanol
13 49-52 Benzene :
Chloroform
8: 2 Green
colour
1 0.89 Ethyl acetate :
Methanol
14 53-56 Benzene :
Chloroform
7 : 3 Green
colour
-- -- Ethyl acetate :
Methanol
15 57-60 Benzene :
Chloroform
6 : 4 Light
green
colour
-- -- Ethyl acetate :
Methanol
16 61-64 Benzene :
Chloroform
5 : 5 Yellowish
green
colour
-- -- Ethyl acetate :
Methanol
17 65-68 Benzene :
Chloroform
4 : 6 Faint
yellow
colour
-- -- Ethyl acetate :
Methanol
18 69-72 Benzene :
Chloroform
3 : 7 Colourless Ethyl acetate :
Methanol
19 73-76 Benzene :
Chloroform
2 : 8 Colourless -- -- Ethyl acetate :
Methanol
20 77-80 Benzene :
Chloroform
1 : 9 Colourless -- -- Ethyl acetate :
Methanol
21 81-84 Chloroform 100 Colourless -- -- Ethyl acetate :
Methanol
22 85-88 Chloroform
: Methanol
9 : 1 Light
yellow
colour
1 0.90 Ethyl acetate :
Methanol
23 89-92 Chloroform
: Methanol
8: 2 Yellow
colour
2 0.89
0.76
Benzene : Ethyl
acetate : Diethyl
amine
24 93-96 Chloroform
: Methanol
7 : 3 Yellow
colour
1 0.78 Benzene : Ethyl
acetate : Diethyl
amine
25 97-
100
Chloroform
: Methanol
6 : 4 Light
yellow
colour
-- -- Benzene : Ethyl
acetate : Diethyl
amine
26 101-
104
Chloroform
: Methanol
5 : 5 Faint
yellow
colour
-- -- Ethyl acetate :
Methanol
27 105-
108
Chloroform
: Methanol
4 : 6 Colourless -- -- Ethyl acetate :
Methanol
28 109-
112
Chloroform
: Methanol
3 : 7 Colourless -- -- Ethyl acetate :
Methanol
29 113-
116
Chloroform
: Methanol
2 : 8 Colourless -- -- Ethyl acetate :
Methanol
30 117-
120
Chloroform
: Methanol
1 : 9 Colourless -- -- Ethyl acetate :
Methanol
31 121-
124
Methanol 100 Colourless -- -- Ethyl acetate :
Methanol
Table No. 6.3 Column Chromatography of ethanol extract on
Chromolaena odorata
Analysis of the isolated compound CO 1
Thin layer Chromatography of the isolated compound CO 1
The isolated compound CO 1 obtained from column chromatography was
analysed by thin layer chromatography using the solvent system Ethyl acetate :
Methanol (4 : 2) and detected by using p-toluenesulphuric acid. It showed the
presence of one brown colour spot with Rf value of 0.09.
Fig. 6.1 TLC of the isolated compound of CO 1
UV Spectroscopy
Fig. 6.2 UV spectroscopy of the isolated compound CO 1
Wavelength (λ max)    : 240 nm
Solvent                        : Chloroform.
IR Spectroscopy
Fig. 6.3 IR Spectrum of isolated compound CO 1
NMR Spectroscopy
Fig. 6.4 NMR Spectrum of isolated compound CO 1
IR spectral data of the isolated compound CO 1
Sr. No Functional groups Frequency cm-1
1 Phenolic O-H 3388.77 cm-1
2 C-H methylene stretch 2983.01 cm-1
3 C-H Stretching vibration 2827.74 cm-1
4 Ketone group 1720.56 cm-1
5 Quinone 1652.09 cm-1
6 Aromatic ring stretch 1511.28 cm-1
7 O-H bending 1401.33 cm-1
8 Alcoholic O-H out of plane 669.32 cm-1
NMR spectral data of the isolated compound CO 1
Sr. No Types of proton Chemical shift, ppm (δ)
1 Ethers (CH-O-R) 3.3, 3.4
2 Phenolic (Ar-O-H) 4.9
3 Aromatic proton (AR-H) 6.2, 6.4
Results
The chemical characterization of the ethanol extract of Chromolaena odorata
is summarized in Table No. 6.1.2. The results indicated the presence of alkaloids,
carbohydrates, glycosides, tanins, triterpenoids, proteins and flavonoids. The TLC
study was carried out and summarized in Table No. 6.2. From the TLC study of the
ethanol extract of Chromolaena odorata, the presence of four spots were observed
as maximum number of spots with Ethyl acetate : Methanol (4:2) using p-
toluenesulphuric acid as detecting agent. The Rf values of the spots were calculated
and found to be 0.42, 0.57, 0.71 and 0.96 respectively. Column chromatography of
the ethanol extract of Chromolaena odorata is summarized in Table No.6.3.
Phytochemical analysis of the isolated compound CO 1 gave positive result for
flavonoids. Thin layer chromatography of the isolated compound CO 1 was carried
out using Ethyl acetate : Methanol (4:2) and p-toluenesulphuric acid as detecting
agent and showed the presence of one brown colour spot. The Rf value was
determined as 0.9.
UV spectra of the isolated compound CO 1 was carried out and data showed
the maximum absorption at 240 nm. IR spectra of the isolated compound CO 1 was
carried out and  data showed the presence of phenolic O-H at 3388.77 cm-1, C-H
methylene stretch at 2983.01 cm-1, C-H stretching vibration at 2827.74 cm-1,
functional group ketone at 1720.56 cm-1, quinone functional group at 1652.09 cm-1,
aromatic ring stretch at 1511.28 cm-1, O-H bending at 1401.33 cm-1, alcoholic O-H
out of plane bend at 669.32 cm-1. NMR spectra of the isolated compound was
carried out and data showed the presence of ether (CH-O-R) at 3.3, 3.4 ppm,
phenolic (Ar-OH) at 4.9 and aromatic proton (Ar-H) at 6.2, 6.4 respectively.
The phytochemical screening and spectral data of the isolated compound
suggested that the isolated compound resembles structural similarities with the
flavonoids.
6.4 Pharmacological screening
In vitro anticancer activity of Chromolaena odorata
The purpose of this assay is to screen drugs for anticancer activity using
cancer cell line of HCT-11 (human colorectal adrenocarcinoma cancer cell line) and
HeLa (human cervical cell line) using MTT assay method.
Extract Cell line Conc
(µg/ml)
% Cell
inhibition
IC50
(µg/ml)
Ethanol extract of
Chromolaena
odorata
HCT116
31.25 26.96±2.008
60.18
62.5 57.59±1.891
125 66.34±2.01
250 85.30±0.9313
500 92.90±0.5224
31.25 21.92±1.652
71.74
62.5 42.15±1.825
HeLa 125 74.13±1.004
250 77.18±0.3528
500 89.13±0.5302
Table No. 6.4.1 Percentage cell inhibition of different concentration of ethanol
extract of Chromolaena odorata
Chart No. 6.4.1 Percentage Cell inhibition of Anticancer activity of
Chromolaena Odorata in human cervical cancer cell line ( HeLa ).
Chart No. 6.4.2 Percentage Cell inhibition of anticancer activity of
Chromolaena Odorata in human colorectal adenocarcinoma cell line (HCT116).
Chart No. 6.4.3 Percentage growth Inhibition of Chromolaena odorata in two
cell lines (HCT-116 and HeLa)
HeLa
HCT
HCT- 116
Control (without sample)
62.5 µg/ml 125 µg/ml
250 µg/ml 500 µg/ml
Fig. 6.4 Inhibition of cancer cell lines by different concentration of ethanol
extract of Chromolaena odorata
HeLa
Control (without sample)
62.5 µg/ml 125 µg/ml
250 µg/ml 500 µg/ml
Fig. 6.5 Inhibition of cancer cell lines by different concentration of ethanol
extract of Chromolaena odorata
Results
The pharmacological screening of the ethanol extract of Chromolaena
odorata was performed as per reported in topic 5.4 of chapter 5. The data of
percentage cell inhibition by ethanol extract of Chromolaena odorata at different
concentrations were presented in Table No. 6.4.1 and Chart No. 6.4.1 and 6.4.2. The
difference in inhibition of cell by ethanol extract of Chromolaena odorata was
presented in Chart No. 6.4.3 Inhibition picture of cancer cell line HCT116 and HeLa
was presented in figure 6.4 and 6.5. The results indicated that ethanol extract of
Chromolaena odorata showed significant inhibition of cell on both cell lines with
IC50 of 60.18 µg/ml in HCT116 and 71.74 µg/ml in HeLa respectively. The result
also showed that percentage inhibition of cell by the ethanol extract of Chromolaena
odorata increases with increase in concentration of extract.
6.5 Discussion
The leaves of Chromolaena odorata linn belonging to the family Asteraceae
has been investigated in a systematic way covering the phytochemical screening and
pharmacological studies.
From the literature survey, it revealed that very less amount of
pharmacological work has been carried on Chromolaena odorata. But no work has
been found during literature survey in the line of anti cancer activity. Therefore it
was thought worthwhile to carry out preliminary phytochemical screening, isolation
and characterization of the isolated compound and pharmacological investigation in
the line of anti cancer activity.
Extraction
The leaves of Chromolaena odorata linn. were collected in the month of July
2011 from Perur, near Perur temple, Coimbatore, Tamilnadu and was authentified
by Dr. M.Palanisamy, Scientist ‘C’ with reference number of
No.BSI/SRC/5/23/2010-11/TECH.1089, Botanical Survey of India, Southern
Regional Centre, Coimbatore-641 003. The collected leaves were dried and using a
mechanical grinder it was made into a coarse powder. The powder was seive
through seive No. 40. 150 gm of the powder was packed in a thimble and extracted
with petroleum ether (60-80 ºC) by continous hot percolation process using Soxhlet
apparatus for 72 hours. The resulting semisolid mass was vacuum dried in a
dessicator to yield (0.75 gm) solid residue. After the extraction with petroleum ether
the same plant material was dried and again extracted with ethanol (95% v/v) for 72
hours in Soxhlet apparatus. The solvent was removed by distillation under reduced
pressure and resulting semisolid mass was vacuum dried to yield (5.80 gm) solid
residue.
Phytochemical screening
Qualitative phytochemical screening were carried out to identify the
phytoconstituents. The petroleum ether extract of Chromolaena odorata contained
alkaloids and triterpenoids.While the ethanol extract showed the presence of
alkaloids, carbohydrates, glycosides, tannins, triterpenoids, proteins and flavonoids.
Thin Layer Chromatography
The thin layer chromtography of the ethanol extract of Chromolaena odorata
obtained showed the presence of four spots with Ethyl acetate : Methanol (4:2) using
p-toluene sulphuric acid as detecting agent. The Rf values were calculated and found
to be 0.42, 0.57, 0.71 and 0.96 respectively.
Column chromatography
Compounds were isolated from Chromolaena odorata by column
chromatography with gradient elution technique with the help of solvent system
petroleum ether, benzene, chloroform and methanol. Phytochemical analysis of the
isolated compound CO 1 showed positive result for flavonoid. TLC of the isolated
compound CO 1 was also carried out using Ethyl acetate : Methanol (4:2) and p-
toluenesulphuric acid as detecting agent and showed the presence of one spot. Rf
value was determined as 0.90. The isolated constituents were purified and
characterized by spectral studies using UV, IR and NMR spectroscopy etc.
UV spectral data showed the maximum absorption at 240nm.
IR spaectral data showed the presence of phenolic O-H at 3388.77 cm-1, C-H
methylene stretch at 2983.01 cm-1, C-H stretching vibration at 2827.74 cm-1,
functional group ketone at 1720.56 cm-1, quinone functional group at 1652.09 cm-1,
aromatic ring stretch at 1511.28 cm-1, O-H bend at 1401.33 cm-1, alcohol O-H out of
plane bend at 669.32 cm-1 respectively.
NMR spectral data showed the presence of ether (CH-O-R) at 3.3, 3.4 ppm,
phenolic (Ar-OH) at 4.9 and aromatic proton (Ar-H) at 6.2, 6.4 respectively.
From the study of phytochemical screening, thin layer chromatography and
spectral studies suggested that the isolated compound resembles structural
similarities with the flavonoids.
Pharmacological screening
Scientific strategies for the in vitro anticancer evaluation of natural products
with biological activity have changed in the past few years. One recent development
is the highly automated bioassay screening based on colorometric methods that
quantify the proloferation of cells. Many biological assays require the measurement
of surviving and/or proliferation of mammalian cells. This can be acheived by MTT
assay, a non-radioactive, fast and economical assay widely used to quantify cell
viability and proliferation.
MTT is a yellow water soluble tetrazolium salt. Metabolically active cells are
able to convert the dye to water insoluble dark blue farmazan by reductive cleavage
of the tetrazolium ring. MTT is cleaved by all living cells but not ny dead cells. The
amount of farmazan generated is directly proportional to the cell number. (DA
Scudiero, et al)
In the present study anticancer activity of ethanolic extact of Chromolaena
odorata was evaluated with MTT assay using cancer cell line of HCT-11 (human
colorectal adrenocarcinoma cancer cell line) and HeLa (human cervical cell line).
The present study demonstrated that ethanol extract of Chromolaena odorata
showed significant inhibition of both cell lines (HCT116 and HeLa). Inhibition of
cell by the ethanol extract of Chromolaena odorata was found to concentration
dependent. On comparison, it was found that percentage inhibition of cell in
HCT116 cell line is more. Thus, in indicated that ethanol extract of Chromolaena
odorata showed more effective in screening anticancer activity using HCT cell line
when compared to HeLA cell line.
The result suggested that ethanol extract of Chromolaena odorata showed
significant anticancer activity with IC50 values of 60.18 µg/ml for HCT116 cell line
and 71.74 µg/ml for HeLA cell line respectively.
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The work presented here dealt with the plant Chromolaena odorata Linn.
towards the isolation of phytoconstituents, characterisation of the isolated compound
by spectral studies using UV, IR and NMR spectroscopy and evaluation of
anticancer activity using cell line HCT116 and HeLa by using MTT assay.
The plant was collected from Perur, near Perur temple, Coimbatore, Tamil
Nadu during the month of July 2011 and was taxonomically identified and
confirmed by the Botanical Survey of India, Southern Circle Tamil Nadu
Agriculture University Campus, Coimbatore, India, with reference number of
No.BSI/SRC/5/23/2010-11/Tech.1089.
The literature survey revealed that very less amount of pharmacological
work has been carried on Chromolaena odorata. Therefore it was thought
worthwhile to carry out preliminary phytochemical screening, isolation and
characterization of the isolated compound and pharmacological investigation in the
line of anticancer activity.
The project work was initiated with the collection of plant, dried under shade
and then powdered with mechanical grinder and passed through sieve No. 40 and
stored in an air tight container. The crushed plant material was extracted by using
petroleum ether (60-80 °C) and ethanol (95% v/v) with the help of Soxhlet apparatus
successively. The percentage yield of petroleum ether and ethanol extracts were 0.75
and 5.80 w/w respectively.
The crude extracts were subjected to preliminary phytochemical screening.
The preliminary phytochemical screening revealed that the extract of Chromolaena
odorata contains alkaloids, flavonoids, glycosides, triterpenoids, tannins and
carbohydrates as major phytoconstituents.
Thin layer chromatography was carried out for ethanol extract by using
various solvent systems. Ethyl acetate : Methanol (4:2) shows the maximum number
of spots with   p-tolunesulphuric acid as detecting agent. The Rf values were
calculated and found to be 0.42, 0.57, 0.71 and 0.96 respectively.
Further crude ethanol extract of Chromolaena odorata linn was subjected for
isolation by using Column chromatography with gradient elution technique with the
help of solvent system petroleum ether, benzene, chloroform and methanol.
Phytochemical test of the isolated compound CO 1 was carried and showed positive
test for flavonoids. Thin layer chromatography of the isolated compound CO 1 was
also carried out by using solvent system Ethyl acetate : Methanol (4:2) and showed
the presence of one spot with detecting agent p-toluenesulphuric acid and Rf value
was determined as 0.90. The isolated constituents were purified and characterized by
spectral studies using UV, IR and NMR spectroscopy etc.
UV spectral data showed the maximum absorption at 240 nm.
IR spectral data showed the presence of phenolic O-H at 3388.77 cm-1, C-H
methylene stretch at 2983.01 cm-1, C-H stretching vibration at 2827.74 cm-1,
functional group ketone at 1720.56 cm-1, quinone functional group at 1652.09 cm-1,
aromatic ring stretch at 1511.28 cm-1, O-H bending at 1401.33 cm-1, alcoholic O-H
out of plane bend at 669.32 cm-1.
NMR spectral data showed the presence of ether (CH-O-R) at 3.3, 3.4 ppm,
phenolic (Ar-OH) at 4.9 and aromatic proton (Ar-H) at 6.2, 6.4 respectively.
From the study of phytochemical screening, thin layer chromatography and
spectral studies suggested that the isolated compound resembles structural
similarities with the flavonoids.
Pharmacological screening of the ethanol extract of Chromolaena odorata
was carried out using using cancer cell line of HCT-11 (human colorectal
adrenocarcinoma cancer cell line) and HeLa (human cervical cell line). The result
showed significant inhibition of cell with IC50 values of 60.18 µg/ml and 71.74
µg/ml respectively. The result also showed that percentage inhibition of cell by the
ethanol extract of Chromolaena odorata increases with increase in concentration of
extract.
In conclusion, from literature survey, preliminary phytochemical screening,
thin layer chromatography study, isolation of active compound by column
chromatography and spectral studies of the isolated compound by UV, IR and NMR
spectroscopy, it reveals that flavonoids may be the secondary metabolite present in
active crude extract of leaves of Chromolaena odorata linn which may be
responsible for pharmacological activity in the line anticancer activity. Considering
the lack and need of drugs, the specific effects of Chromolaena odorata reported in
the present study is of enormous interest and deserves further investigation using
more experimental paradigms for further confirmation to isolate and characterize the
active compounds.
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